Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Infectious Disease Specialists (EU)

July 28, 2008
HLA screening for ABV hypersensitivity reaction
By a GLG Expert Contributor
Analysis of: F.D.A. Urges Genetic Test Before Giving AIDS Drug (www.nytimes.com)
After the extensive studies published (Mallal et al), it becomes mandatory to perform a genetic HLA screening before starting abacavir-containing antiretroviral associations. Problems are recognizable in these points: - laboratories are not capable to front an exaggerated request of HLA typing; - ad-hoc...
February 27, 2008
To consider the possible role of the new NNRTI etravirine in the treatment of HIV infection
By a GLG Expert Contributor
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix (www.pipelinereview.com)
Etravirine is a novel and very promising NNRTI since it has not cross-resistance with the existing NNRTIs (efavirenz and nevirapine), and also encompasses excellent efficacy, convenience, and a good tolerability.
February 11, 2008
A new NNRTI strong,safe and respectful of other similar drugs next use
By a GLG Expert Contributor
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix (www.pipelinereview.com)
HIV therapy must be the strongest and the most safe therapy ; NNRTI are the key drugs for this kind of therapy. When you,doctor,begin a  naive HIV therapy, you must think that your patient should be treated for a very long time , maybe for a whole life period ; it'simportant...
December 20, 2007
Very Good News For HIV Infected Individuals. Sandro Vento, MD. Azienda Ospedaliera di Cosenza, Italy
By a GLG Expert Contributor
Analysis of: European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection (www.pipelinereview.com)
Atripla is a fixed combination in a single pill of three excellent antiretroviral drugs with very good pharmacokinetics profile and fairly good tolerability. It will have a considerable impact on compliance as it can be taken once daily. If compliance will be as good as predictable, the chances that...

Page : 11 to 4 of 4

Analytics


Generated at 2009-01-08T13:34:52.320